

# *In vitro* prototyping of limonene biosynthesis using cell-free protein synthesis

Quentin M. Dudley<sup>1</sup>, Ashty S. Karim, Connor J. Nash, Michael C. Jewett<sup>\*</sup>

Department of Chemical and Biological Engineering and Center for Synthetic Biology, Northwestern University, Evanston, IL, 60208, USA

## ARTICLE INFO

### Keywords:

Cell-free metabolic engineering  
Limonene  
iPROBE  
Cell-free metabolic pathway prototyping  
Cell-free protein synthesis  
Synthetic biology

## ABSTRACT

Metabolic engineering of microorganisms to produce sustainable chemicals has emerged as an important part of the global bioeconomy. Unfortunately, efforts to design and engineer microbial cell factories are challenging because design-build-test cycles, iterations of re-engineering organisms to test and optimize new sets of enzymes, are slow. To alleviate this challenge, we demonstrate a cell-free approach termed *in vitro* Prototyping and Rapid Optimization of Biosynthetic Enzymes (or iPROBE). In iPROBE, a large number of pathway combinations can be rapidly built and optimized. The key idea is to use cell-free protein synthesis (CFPS) to manufacture pathway enzymes in separate reactions that are then mixed to modularly assemble multiple, distinct biosynthetic pathways. As a model, we apply our approach to the 9-step heterologous enzyme pathway to limonene in extracts from *Escherichia coli*. In iterative cycles of design, we studied the impact of 54 enzyme homologs, multiple enzyme levels, and cofactor concentrations on pathway performance. In total, we screened over 150 unique sets of enzymes in 580 unique pathway conditions to increase limonene production in 24 h from 0.2 to 4.5 mM (23–610 mg/L). Finally, to demonstrate the modularity of this pathway, we also synthesized the biofuel precursors pinene and bisabolene. We anticipate that iPROBE will accelerate design-build-test cycles for metabolic engineering, enabling data-driven multiplexed cell-free methods for testing large combinations of biosynthetic enzymes to inform cellular design.

## 1. Introduction

Isoprenoids are a promising class of molecules with over 40,000 known structures and potential uses as pharmaceuticals, flavors, fragrances, pesticides, disinfectants, and chemical feedstocks (Bohlmann and Keeling, 2008; George et al., 2015; Jongedijk et al., 2016). While there have been demonstrations of cellular isoprenoid production at commercial scales (Benjamin et al., 2016; Paddon et al., 2013), efforts to engineer strains for new products have proved challenging.

In particular, efforts to explore large sets of heterologous expression conditions are constrained by the need to re-engineer the cell in each iteration. This constraint has often limited cellular approaches to small sets of unique strains, with these sets focused on modifying expression conditions such as ribosome binding site strength (Li et al., 2019; Nowroozi et al., 2014), enzyme expression timing (Alonso-Gutierrez et al., 2015), and plasmid architecture (Yang et al., 2016). New developments in parallelized DNA assembly and robotic liquid handling have enabled the testing of 122 plasmid architectures for the 16-gene refactored nitrogen fixation gene cluster from *Klebsiella oxytoca* (Smanski et al., 2014), the construction of “Marionette” strains for prototyping 243 different expression profiles for lycopene pathway

enzymes (Meyer et al., 2019), and the characterization of thousands of ribosome binding site combinations for tuning the production of limonene (Jervis et al., 2019) and naringenin (Zhou et al., 2019). However, these efforts have not been adapted for characterizing large combinations of enzyme homologs, which can significantly enhance performance (Ma et al., 2011; Tsuruta et al., 2009).

Cell-free metabolic engineering offers tremendous flexibility to quickly tune biosynthetic pathway enzymes, reaction substrates, and cofactors (Dudley et al., 2015; Silverman et al., 2019), giving access to test hundreds of unique pathway expression conditions. Cell-free systems using purified enzymes have shown utility in prototyping metabolic pathways for a range of compounds including fatty acids (Liu et al., 2010), farnesene (Zhu et al., 2014), phenylalanine (Ding et al., 2016), and non-oxidative glycolysis (Bogorad et al., 2013). Crude lysates are becoming increasingly popular for prototyping metabolism because lysates contain endogenous metabolism, diverse substrates, and cofactors (Míguez et al., 2019; Schuh et al., 2020). Additionally, when provided with an energy source, amino acids, NTPs, and excess cofactors, crude lysates contain the translational machinery for cell-free protein synthesis (CFPS), which enables rapid production of proteins (Carlson et al., 2012; Casini et al., 2018; Chen et al., 2020; Des Soye

<sup>\*</sup> Corresponding author.

E-mail address: [m-jewett@northwestern.edu](mailto:m-jewett@northwestern.edu) (M.C. Jewett).

<sup>1</sup> Present address: Earlham Institute, Norwich Research Park, Colney Lane, Norwich, NR4 7UZ, United Kingdom.

et al., 2019; Huang et al., 2018; Jaroentomeechai et al., 2018; Jewett et al., 2008; Kightlinger et al., 2019; Lin et al., 2020; Silverman et al., 2019; Stark et al., 2018, 2019). CFPS decreases the time from DNA to soluble protein and can be used to synthesize functional catalytic enzymes (Karim and Jewett, 2016). The hybrid approach of cell-free protein synthesis metabolic engineering (CFPS-ME) has been successfully adapted to prototype production of polyhydroxyalkanoate (Kelwick et al., 2018), 1,4-butanediol (Wu et al., 2015, 2017), and styrene (Grubbe et al., 2020). Yet, even with the rapid ability to synthesize and test enzymes *in vitro*, these examples have typically utilized only a small set of enzyme homologs in their optimization strategies.

In this work, we describe a modular, high-throughput isoprenoid production platform for quickly prototyping enzyme homologs, concentrations, and reaction conditions. By expressing pathway enzymes using CFPS in separate reactions and then mixing them together in known concentrations, we modularly assemble pathway combinations for production of the monoterpene limonene. This conceptual approach, called *in vitro* Prototyping and Rapid Optimization of Biosynthetic Enzymes (iPROBE), has previously been shown to shorten the time to prototype 3-hydroxybutyrate and *n*-butanol production from more than 6 months to a few weeks for improving *in vivo* biosynthesis in *Clostridium* (Karim et al., 2019). Notably, iPROBE demonstrates a strong correlation between in cell and cell-free pathway performance (Karim et al., 2019).

Here we expand the iPROBE approach to longer isoprenoid pathways. We use the 9-heterologous enzyme pathway to limonene as a model pathway (Fig. 1A). We screened 580 unique pathway combinations testing 54 different enzyme variants in several reaction conditions. By screening hundreds of enzyme sets and various reaction formats, we were able to improve production 25-fold from our initial setup. We also demonstrated pathway modularity by swapping out the isoprenoid synthetase to produce pinene and bisabolene. Our results suggest that previous cell-free isoprenoid systems which have so far, to our knowledge, reported fewer than 20 enzyme and reaction combinations per study (Chen et al., 2013; Dirkmann et al., 2018; Korman et al., 2014, 2017; Rodriguez and Leyh, 2014; Zhu et al., 2014), could benefit from screening more enzyme variants. iPROBE provides the ability to test dozens of enzyme homologs in hundreds of combinations without needing to re-engineer a cell or re-assemble DNA. As a result, we expect iPROBE to enhance efforts to prototype isoprenoid and other complex biosynthetic pathways for cellular or cell-free biomanufacturing.

## 2. Materials and methods

### 2.1. Strain, plasmid, and lysate preparation

All enzyme sequences tested in CFPS were cloned into the pJL1 backbone (Addgene #69496). To assemble plasmids encoding previously tested enzyme homologs (Dudley et al., 2019), the coding sequence of each enzyme was PCR-amplified using forward primer [ttaaactttaagaaggagatatacatatggagaaaaaacNNNNNNNNNNNNNNNNNNNNNN where the 3' region encodes the gene sequence starting at the second codon (i.e. right after the ATG)] and reverse primer [ttcctttcggtgttagcagccggtgcacNNNNNNNNNNNNNNNNNNNNNN where the 3' region encodes the C-terminus of the gene sequence including the stop codon]. The forward primer adds an N-terminal expression tag to improve cell-free expression which consists of a 15 nucleotide, AT-rich sequence encoding the first five amino acids (Met-Glu-Lys-Lys-Ile, MEKKI) of chloramphenicol acetyl transferase which was used as a reporter plasmid during development of the *E. coli* CFPS system (Jewett and Swartz, 2004; Swartz et al., 2004). Addition of the MEKKI sequence demonstrably improved *in vitro* expression (Fig. S1). The PCR fragment was then mixed with pJL1 backbone digested with the restriction enzymes NdeI and SalI along with reagents for Gibson assembly (Gibson et al., 2009).

To obtain additional sequences for testing, we first generated phylogenetic trees of pathway homologs using Geneious bioinformatics software (Auckland, New Zealand). Sequences for EC 2.7.1.36 (MK), EC 2.7.4.2 (PMK), EC 4.1.1.33 (PMD), EC 5.3.3.2 (IDI), and EC 4.2.3.16/20 (LS) were downloaded from the BRENDA database (Scheer et al., 2010) and aligned in Geneious using MUSCLE 3.8.425 (Edgar, 2004) along with a Jukes-Cantor genetic distance model and a Neighbor-Joining tree build method. To choose uncharacterized homologs for testing, we selected 15 sequences from branches of the phylogenetic tree not represented by 30 previously characterized homologs (Table S1). These 45 sequences were then codon optimized for expression in *E. coli* and synthesized by Gen9 (Cambridge, MA) or Twist Bioscience (San Francisco, CA). Sequences were cloned into the pJL1 backbone by Gibson Assembly (Gen9) or by the synthesis company (Twist); nucleotide sequences are available in Appendix S1. Gene sequences contained two sequential NdeI recognition sequences at the start of each gene resulting in catATGCATATGGAGAAAAAATC (encoding MHMEKKI) instead of catATGGAGAAAAAATC (encoding MEKKI). Upon comparison, the CFPS expression was equivalent for both N-terminal expression tags (Fig. S2) and both were tags ultimately used (see Table S1).


Lysates pre-enriched with a pathway enzyme were generated as described previously (Dudley et al., 2019). To generate CFPS S30 lysate for cell-free protein synthesis, BL21 Star(DE3) *E. coli* was grown in 1 L of 2xYTPG media in Tunair™ shake flasks at 37 °C (250 rpm). Expression of T7 RNA polymerase was induced at OD<sub>600</sub> = 0.6 by addition of 0.1 mM IPTG and cells were harvested by centrifugation at OD<sub>600</sub> = 3.0. Pellets were washed twice in S30 buffer (10 mM tris acetate pH 8.2, 14 mM magnesium acetate, 60 mM potassium acetate, no dithiothreitol (DTT)), flash frozen, and stored at –80 °C. Cell pellets were then thawed on ice, resuspended in S30 buffer without DTT (0.8 mL per gram cell pellet), lysed via pressure homogenization with one pass at 20,000 psi (Avestin EmulsiFlex-B15), and centrifuged twice at 30,000 x g for 30 min. The supernatant (i.e. lysate) was transferred to a new container without disturbing the pellet, aliquoted, and flash frozen for storage at –80 °C. Optimal magnesium concentration was determined to be 8 mM based on expression of the plasmid pJL1-sfGFP (Addgene #69496) encoding superfolder Green Fluorescent Protein (sfGFP).

### 2.2. Cell-free protein synthesis reactions

All CFPS reactions used a modified PANox-SP formula (Jewett and Swartz, 2004; Kwon and Jewett, 2015). Each reaction contains 13.3 µL of S30 extract for a 50 µL CFPS reaction (Fig. S3) in addition to ATP (1.2 mM), GTP, UTP, CTP (0.85 mM each), folinic acid (34 µg/mL), *E. coli* tRNA mixture (170 µg/mL), 20 standard amino acids (2 mM each), NAD<sup>+</sup> (33 mM), coenzyme A (CoA) (0.27 mM), oxalic acid (4 mM), spermidine (1.5 mM), putrescine (1 mM), HEPES (57 mM), potassium glutamate (134 mM), ammonium glutamate (10 mM), magnesium glutamate (8 mM), phosphoenolpyruvate (PEP) (33 mM), and plasmid (13.3 µg/mL) encoding the metabolic pathway enzyme. T7 RNA polymerase was not added to CFPS reactions since extracts were induced with IPTG during cell growth. CFPS reactions of pathway enzymes are incubated for 20 h at 30 °C or 16 °C (Table S1), flash frozen on liquid nitrogen, and stored at –80 °C.

### 2.3. Quantification of CFPS protein production using radioactive amino acid incorporation

To measure the amount of protein produced in a CFPS reaction, <sup>14</sup>C-leucine (10 µM) was supplemented in addition to the 20 standard amino acids. Reactions were centrifuged at 21,000 x g for 10 min to pellet insoluble proteins for measurement of soluble protein. Reactions were quenched by addition of equal volume 0.5 M potassium hydroxide and pipetted onto two separate 96-well fiberglass papers (PerkinElmer Printer Filtermat A 1450-421, 90x120mm) and dried. One paper was



**Fig. 1. Cell-free limonene production using enzymes sourced from a variety of organisms.** (A) The metabolic pathway from glucose to limonene requires nine enzymes plus glycolysis activity present in the lysate. (B) Phylogenetic comparison of enzyme sequences to select diverse enzyme homologs for testing. Scale bars denote substitutions per site. Ag, *Abies grandis* (grand fir); Bm, *Bacopa monniera*; Bp, *Bordetella petrii*; Bs, *Bacillus subtilis*; Cl, *Citrus limon* (lemon); Da, *Delftia acidovorans*; Ec, *Escherichia coli* (for ACAT, FPPS, IDI); Eremococcus coleocola (for PMK); Ef, *Enterococcus faecalis*; Hm, *Haloferax mediterranei*; La, *Lavandula angustifolia* (lavender); Mm, *Methanosarcina mazei*; Ms, *Mentha spicata* (spearmint); Mx, *Myxococcus xanthus*; Nm, *Nitrosopumilus maritimus*; Pa, *Picea abies* (Norway spruce); Pf, *Perilla frutescens* (wild sesame); Pg, *Picea glauca* (white spruce); Pk, *Picrorhiza kurroa*; Pm, *Pseudomonas mevalonii*; Pz, *Paracoccus zeaxanthinifaciens*; Sa, *Staphylococcus aureus*; Sc, *Saccharomyces cerevisiae*; Sc, *Streptomyces clavuligerus*; Sl, *Solanum lycopersicum* (tomato); Sp, *Streptococcus pneumoniae*; St, *Streptomyces* sp strain CL190 (for IDI); *Streptomyces* sp. Strain KO-3988 (for GPPS); *Schizonepeta tenuifolia* (for LS); Th, *Tetragenococcus halophilus*; Zg, *Zobellia galactanivorans*; AA-CoA, acetoacetyl-CoA; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; Mev, mevalonate; Mev-P, mevalonate-5-phosphate; Mev-PP, mevalonate pyrophosphate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; GPP, geranyl pyrophosphate; ACAT, acetyl-CoA acetyltransferase; HMGS, hydroxymethylglutaryl-CoA synthase; HMGR, hydroxymethylglutaryl-CoA reductase; MK, mevalonate kinase; PMK, phosphomevalonate kinase; PMD, pyrophosphomevalonate decarboxylase; IDI, isopentenyl pyrophosphate isomerase; GPPS, geranyl diphosphate synthase; LS, limonene synthase.

subjected to three trichloroacetic acid (TCA) washes (15 min each at 4 °C) to precipitate proteins and dried after rinsing with 100% ethanol. Scintillation wax (PerkinElmer MeltiLex A 1450-441 73x109 mm) was applied and radioactivity was measured using liquid scintillation counting via a MicroBeta2 (PerkinElmer, Waltham, MA). Protein concentration was determined as previously described (Jewett et al., 2008; Jewett and Swartz, 2004) by comparing radioactivity in the total reaction to that of precipitated protein using Equation (1) (Appendix S2).

#### 2.4. Mixing of CFPS reactions and pre-enriched lysates to produce limonene

All limonene synthesis reactions are 30  $\mu$ L in total volume and can be divided into the “CFPS fraction” and the “substrate/lysate/cofactor fraction”. The 15  $\mu$ L CFPS fraction contains six to nine CFPS reactions (thawed on ice) and mixed at concentrations dictated by the experiment. “Blank” CFPS reaction (50  $\mu$ L volume containing all CFPS reagents, no plasmid, and incubated for 20 h at 30 °C, Fig. S4) is added until the total volume of CFPS fraction is 15  $\mu$ L. The 15  $\mu$ L “substrate/



lysate/cofactor fraction” includes the following components (concentrations are given with respect to the fully assembled 30  $\mu$ L limonene synthesis reaction): 4 mM magnesium glutamate, 5 mM ammonium glutamate, 65 mM potassium glutamate, 200 mM glucose, 50  $\mu$ g/mL kanamycin, and 100 mM Bis-Tris (pH 7.4). Since “CFPS fraction” already contains glutamate salts, supplementation of glutamate salts in the “substrate/lysate/cofactor fraction” maintains the overall cation concentrations at 8 mM magnesium, 10 mM ammonium, and 130 mM potassium. Optionally, cofactors ATP, NAD<sup>+</sup>, and CoA can be supplemented as well (concentrations are given with respect to the fully assembled 30  $\mu$ L limonene synthesis reaction). The “substrate/lysate/cofactor fraction” also includes fresh S30 lysate(s) at a total protein concentration of 4 mg/mL. Total protein is measured Bradford assay with bovine serum albumin (BSA) as the standard using a microplate protocol (Bio-Rad, Hercules, CA). Typically, three S30 lysates are added each pre-enriched for a single enzyme (*Ec*ACAT, *Sch*MGs, and *Msl*S) (Dudley et al., 2016, 2019); each is included at a total protein concentration of 1.33 mg/mL. Based on the level of protein overexpression measured by densitometry (Table S2), the final concentration of enriched enzyme in the limonene synthesis reaction is estimated to be  $\sim$ 4.7  $\mu$ M for *Ec*ACAT,  $\sim$ 5.5  $\mu$ M for *Sch*MGs, and  $\sim$ 3.4  $\mu$ M for *Msl*S, respectively. “Blank lysate” (generated from BL21(DE3) containing no expression plasmid) is added in place of an enzyme-enriched lysate if the given enzyme is included as a CFPS reaction. Limonene synthesis reactions are incubated at 30 °C with a 30  $\mu$ L dodecane overlay. Limonene in the overlay was quantified at 3, 4, 5, 6, and 24 h using GC-MS and other metabolites in the reaction were quantified by HPLC as previously described (Dudley et al., 2016, 2019). Using the same GC-MS method (Dudley et al., 2019), peaks within the 93.1 m/z extract ion chromatogram (EIC) were integrated to quantify  $\alpha$ -pinene (2.46 min),  $\beta$ -pinene (2.62 min), and bisabolene (4.63 min). See Table S3 and Supplementary Data File 1 for systematic description of the variable reaction components in each enzyme set tested. The TREE score is calculated using Equations (2) and (3) described in Appendix S2.

### 3. Results

The goals of this work were to (1) apply the iPROBE framework to build the nine-enzyme pathway to produce limonene, (2) assess the impact of cofactors on cell-free enzyme performance, (3) iteratively optimize the enzymatic production of limonene, and (4) extend the pathway to additional isoprenoids. We selected limonene biosynthesis as our model system given its importance as a high-value specialty chemical (Jongedijk et al., 2016) and our previous work with the pathway. In our previous work, we demonstrated cell-free biosynthesis of limonene in crude cell lysates whereby the enzymes were heterologously overexpressed *in vivo* before lysate preparation (Dudley et al., 2019) (Fig. 1A). Crude cell lysates contain endogenous enzymes for glycolysis that regenerate NADH and convert glucose to acetyl-CoA, providing the starting intermediate for limonene biosynthesis. Upon mixing together of selectively enriched lysates comprising all necessary enzymes, the full pathway could be activated. This work gave a starting point for applying iPROBE, wherein we would utilize lysates enriched not by heterologous protein expression prior to lysis, but by expressing the protein from a DNA template in the reaction via CFPS.


#### 3.1. Application of iPROBE to a nine-enzyme pathway for producing limonene

We established a cell-free pathway to produce limonene and identified candidate sets of enzyme homologs to improve production. First, we built a cell-free system to produce limonene using a previously characterized set of enzymes with the iPROBE approach. Each enzyme is produced individually via CFPS and the resulting “CFPS-enriched reactions” are mixed with glucose substrate and cofactors to produce the target molecule limonene (Fig. 2A). Nine enzymes were needed


including: acetyl-CoA acetyltransferase (ACAT) from *E. coli*, hydroxymethylglutaryl-CoA synthase (HMGS) from *Saccharomyces cerevisiae*, hydroxymethylglutaryl-CoA reductase (HMGR) from *Pseudomonas mevalonii*, mevalonate kinase (MK), phosphomevalonate kinase (PMK), and pyrophosphomevalonate decarboxylase (PMD) from *S. cerevisiae*, isopentenyl pyrophosphate isomerase (IDI) from *E. coli*, geranyl diphosphate synthase (GPPS) from *Picea abies*, and limonene synthase (LS) from *Mentha spicata* (Dudley et al., 2019). This initial enzyme set 1.0 produced 0.17 mM  $\pm$  0.007 mM limonene (Fig. S5), demonstrating the ability of the cell-free approach to reconstitute the biosynthesis pathway from cell-free synthesized enzymes.

We next wanted to use iPROBE to rapidly characterize combinations of enzyme homologs, which can significantly enhance performance because catalytic rate, substrate specificity, and feedback inhibition can vary widely across related enzymes in both primary (Maeda, 2019) and secondary (Schmidt et al., 2018) metabolism. Therefore, we generated phylogenetic trees for several pathway steps using all available sequences in the BRENDA enzyme database (Scheer et al., 2010) (Fig. 1B). We then selected 45 sequences encoding homologs of the nine enzymes of the mevalonate pathway to limonene (Appendix S1) and assembled them into plasmids for cell-free expression. The first thirty sequences were chosen because they have been kinetically characterized or used in previous metabolic engineering efforts (Table S1). Then, to expand the diversity of sequence space explored, we randomly selected fifteen additional enzyme homologs from phylogenetic clades not represented in the first set of enzymes. Within the randomly selected group, we biased selection towards homologs suspected to be interesting (e.g., the MK, PMK, PMD, and IDI sequences from *Paracoccus zeaxanthinifaciens* ATCC 21588, a marine bacteria that produces high levels of the isoprenoid zeaxanthin (Berry et al., 2009; Berry et al., 2003)).

Fifty-one different pathway combinations of the candidate enzymes selected were assembled using iPROBE and screened for limonene production. CFPS generated soluble protein (> 30% of total protein) for 40 of the 54 enzymes (Fig. 2B). Reduced temperature is a known strategy for improving heterologous protein folding in living cells (Francis and Page, 2010) as well as in cell-free systems (Fujiwara et al., 2013; Li et al., 2017). By decreasing the CFPS incubation temperature from 30 °C to 16 °C (Kataeva et al., 2005; Piserchio et al., 2009), we increased soluble protein yields for the remaining 14 enzymes (Fig. S6). To test metabolic activity, iPROBE reactions were assembled containing the enzyme homolog of interest plus the remaining set of initial base-case pathway enzymes (enzyme set 1.1, which includes pre-enriched lysates of *Ec*ACAT, *Sch*MGs, and *Msl*S (Fig. S7)). We measured limonene initial rate from 3 to 6 h (Fig. 2C) and final titer at 24 h (Fig. 2D) and then ranked each of these 51 different pathway combinations based on a combined Titer, Rate, and Enzyme Expression (TREE) score (Fig. 2E). This score is a simple, empirical, aggregate value of final titer at 24 h (mM), initial rate (mM/h), and average solubility of 9 expressed enzymes (%) (Appendix S2 (Karim et al., 2019)). In comparing the TREE score for each condition (Fig. 2E), we found 2 HMGR, 4 MK, 3 PMK, 4 PMD, 7 IDI, 1 GPPS, and 3 LS homologs with similar performance relative to the initial base-case homolog (black bars, Fig. 2). This approach also served as a quick way to rule out several homologs of MK, PMK, PMD, and LS with much lower (or zero) activity; these homologs were excluded from further testing. The relative activity of different HMGRs is similar to our previous study using pre-enriched lysates (Dudley et al., 2016), as well as *in vivo* pathway testing (Ma et al., 2011), which suggests that expression of enzymes via CFPS produces proteins with similar properties to those generated with these other methods. Finally, we highlight that the concentration of limonene synthase (pre-enriched lysate > CFPS-enriched lysate (red bars Fig. 2E), see Fig. S7) correlated with increased limonene production which is consistent with *in vivo* results (Alonso-Gutierrez et al., 2015). Unfortunately, no improved monoterpene synthase over the starting limonene synthase was identified.



**Fig. 2.** Cell-free expression of enzyme homologs and initial measurement of limonene production. (A) Cell-free protein synthesis (CFPS) generates “CFPS-enriched reactions” where each individual reaction expresses a single enzyme homolog. Additionally, enzymes can be overexpressed *in vivo* and the cell subsequently lysed to generate “pre-enriched lysates”. Mixing of glucose substrate and cofactors with enzyme-enriched extracts produces limonene. (B) CFPS yields for 54 different enzymes. CFPS reactions with soluble/total protein below 30% (Fig. S6) were incubated at 16 °C instead of 30 °C; the amount of soluble protein increased for all 14 proteins. Values represent averages ( $n = 3$ ) and error bars represent 1 standard deviation. (C–D) Cell-free limonene production. Using various enzyme homologs generated by CFPS, the initial rate from 3 to 6 h (C) and titer at 24 h (D) of limonene were measured. The standard reaction included 1.0 μM *Pm*HMGR, 0.4 μM *Sc*MK, 0.4 μM *Sc*PMK, 0.4 μM *Sc*PMD, 2.0 μM *Ec*IDI, and 3.0 μM *Pa*GPPS plus pre-enriched lysates for *Ec*ACAT, *Sc*HMGS, and *Ms*LS (enzyme set 1.0, black bars). Unless noted by (\*, see Table S3 for details), each enzyme homolog is substituted for the standard enzyme at the same concentration. LS homologs are generated via CFPS and compared at 1.0 μM in a reaction lacking the *Ms*LS pre-enriched lysate. Reactions labeled (–) are negative controls without the designated enzyme. The initial rate value is the slope of a linear regression of four data points at 3, 4, 5, and 6 h and error bars are the associated standard error (see Appendix S2). The values for limonene at 24 h represent averages ( $n = 3$ ) and error bars represent 1 standard deviation. (E) the TREE (Titer, Rate, and Enzyme Expression) score is an empirically generated aggregate value of enzyme solubility, initial rate, and final titer that enables ranking of enzyme homologs. The (+) symbol represents homologs included in enzyme set 2.0. Error bars represent propagated error from the three components (see Appendix S2).



**Fig. 3.** Using a new enzyme homolog set and optimizing cofactor concentrations accentuates differences between GPPS and LS homologs. (A) Comparison of initial enzyme homologs (enzyme set 1.1) and an improved set 2.0 containing new homologs for HMGR, MK, PMK, and IDI. Values represent averages ( $n = 3$ ) and error bars represent 1 standard deviation. (B) Supplementation of cofactors  $\text{NAD}^+$ , CoA, and ATP improves limonene rate, titer, and TREE score (Fig. S8) compared to no additional cofactors (blue box). Four reaction conditions (in blue, yellow, and green boxes) were selected as cofactor conditions for further experiments. (C) TREE scores of PaGPPS and PgGPPS (the best two GPPS homologs in Fig. 2E) under different enzyme concentrations. These data informed the reduction of GPPS to 1.0  $\mu\text{M}$  for enzyme set 2.2. (D) Re-testing of LS homologs derived from CFPS at a higher concentration (1.8  $\mu\text{M}$ ) and using supplemented cofactors. Values represent TREE scores and error bars represent propagated error (see Appendix S2). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

### 3.2. Cofactors are a key parameter in testing multi-enzyme pathways

We next wanted to compare the best enzymes from the activity screen to enzyme set 1.1. To do this, we selected six homologs as best candidates using the TREE score metric (Fig. 2E) for enzyme set 2.0: HMGR from *Bordetella petrii*, MK from *Methanosarcina mazei*, PMK from *Enterococcus faecalis*, PMD from *S. cerevisiae*, IDI from *Streptomyces clavuligerus*, and GPPS from *Picea abies* (Norway spruce). Each selected homolog was highest performing in the TREE score with the exception of *Mm*MK, which was chosen over similarly performing homologs due to its known lack of inhibition from downstream isoprenoid metabolites (Primak et al., 2011). We then compared the initial enzyme set 1.1 to the improved set 2.0 containing new homologs for HMGR, MK, PMK, and IDI over 96 h and found that enzyme set 2.0 did not improve limonene production (Fig. 3A). While the first round of enzyme screening was successfully able to identify active and inactive enzyme homologs, there were only small differences between active homologs (Fig. 2E; Fig. 3A).

We next sought to increase cell-free limonene synthesis by optimizing cofactors and tuning enzyme concentrations. Cofactors are important parameter in optimizing the performance of *in vitro* enzyme pathways (Dudley et al., 2016; Karim et al., 2018; O’Kane et al., 2019). We have previously shown 100-fold differences in HMG-CoA

concentrations across 768 unique cofactor conditions of ATP,  $\text{NAD}^+$ , and CoA (O’Kane et al., 2019). Therefore, we tested enzyme sets 1.1 and 2.0 in 18 different cofactor conditions (Fig. 3B). During this optimization, we found that enzyme set 2.0 is better than or equivalent to enzyme set 1.1 in all cofactor conditions but the improvements are more pronounced at optimized cofactor conditions. The best conditions with enzyme set 2.0 increased the TREE score by two-fold with a limonene initial rate and titer at 24 h of  $0.113 \pm 0.010$  mM/hour and  $1.73 \pm 0.23$  mM, respectively (Fig. S8). Next, we wanted to reduce the concentration of enzymes to leave additional volumetric space in the reaction for other CFPS-derived enzymes and potentially differentiate less-active homologs from more-active ones. We titrated the concentration of each CFPS-derived pathway enzyme individually using enzyme set 2.0 (Fig. S9) and found that we could reduce the concentrations of HMGR, MK, PMK, PMD, and IDI (enzyme set 2.1) to produce equivalent levels of limonene (Fig. S9G).

We next examined GPPS, a key enzyme that directs metabolic flux towards ten-carbon GPP and competes with native metabolism which typically generates fifteen-carbon farnesyl pyrophosphate. At high protein concentrations (3  $\mu\text{M}$ ), PaGPPS from *Picea abies* produces the highest limonene final titer, however PgGPPS from *Picea glauca* has a higher productivity from 3 to 6 h and produces the best TREE score at a lower concentration (1  $\mu\text{M}$ ) (Fig. 3C; Fig. S10). We hypothesize that



PgGPPS has higher catalytic rate than PaGPPS but is less stable and is inactivated as the reaction proceeds. We therefore reduced the concentration of GPPS from 3.0  $\mu$ M (Set 2.1) to 1.0  $\mu$ M (Set 2.2) for further experiments. This enabled re-testing of all LS homologs at a higher concentration (including those that did not express well in the cell-free system). As before, the pre-enriched lysate of MsLS from *Mentha spicata* produces the highest TREE score but the difference was far more pronounced when using PgGPPS rather than PaGPPS (Fig. 3D; Fig. S11). This result highlights the importance of testing enzyme homologs in a variety of pathway contexts. Additionally, the increased substrate supply and higher concentration of low-activity synthases (LaLS, SLS, PflS) enabled characterization of their product profile since monoterpene synthases are known to have promiscuous enzyme activity (Leferink et al., 2016). We found that the terpene synthase from *Solanum lycopersicum* (tomato) produces camphene in addition to limonene (Fig. S12) (Falara et al., 2011; Leferink et al., 2016), suggesting that iPROBE could be a useful tool for enzyme profiling, particularly when coupled to untargeted analysis methods.

### 3.3. Iterative screening of active enzyme homologs under multiple cofactor conditions

To demonstrate the full potential of iPROBE, we tested all active enzyme homologs in an iterative experimental approach that characterized 102 enzyme sets tested in four different cofactor concentrations for a total of 408 unique combinations (Fig. 4). The four different cofactor conditions explore different concentrations of CoA, ATP, and NAD<sup>+</sup>. At this point, the primary experimental limitation was not enzyme expression or pathway assembly but product quantitation via GC-MS; this prohibited testing the full combinatorial space of  $6 * 8 * 5 * 5 * 6 * 4 * 2 = 57,600$  enzyme sets, which could have otherwise been achieved with automated liquid handling and assembly of cell-free biosynthesis units. The iterative testing approach started by substituting each of the six active GPPS homologs and measuring the TREE score under four different cofactor conditions (24 unique conditions; Round 3.x) (Fig. 4A). In an effort to capture enzymes that were most active under multiple cofactor conditions, the two enzyme sets with the highest average TREE score over four cofactor concentrations (Fig. 4B; Fig. S13) were selected to move forward in the screen. These sets, differing in GPPS homolog, were then used to test the eight active IDI homologs combinatorially. We assembled 64 unique pathway conditions (enzyme sets and cofactor conditions; Round 4.x) and measured TREE scores for each (Fig. 4B; Fig. S13). Four enzyme sets were selected and carried forward to be the context for combinatorial testing of all PMD homologs (80 unique conditions; Round 5.x). Thereafter, each experiment used the best scoring five conditions from the previous iteration to test active PMK (Round 6.x), PMD (Round 7.x), and HMGR (Round 8.x) homologs sequentially.

The higher limonene production and reduced enzyme concentrations proved to be a more stringent screen for comparing enzyme homologs relative to Fig. 2. The iterative experiment found clear differences between MK and PMD homologs that produced the same amount of limonene in earlier experiments (Fig. 4C, Fig. S14). Additionally, we found that EcIDI from *E. coli* (one of the most common enzymes used for *in vivo* terpenoid production) is far less active at reduced concentration compared to other IDI homologs. Finally, we wish to highlight that some enzyme sets showed a variable ranking depending on which cofactor concentration was used. For example, SaHMGR, SaMK, and PzPMK prefer no supplemental CoA while StGPPS is highly active under optimal cofactors but quite low without cofactor supplementation (Fig. S15). The final enzyme set 9.0 included EcACAT, ScHMGR, BpHMGR, MmMK, PzPMK, ScPMD, SIIDI, PgGPPS, and MsLS (Fig. 4D). Relative to our baseline enzyme set 1.1, the final conditions improved limonene initial rate and final titer by 6-fold and 4-fold, respectively.

### 3.4. Bioproduction of additional terpenoids


With an optimized set of enzymes at hand, we aimed to demonstrate the modularity and flexibility of the cell-free system by extending the pathway to additional products. To achieve this goal, we replaced the final enzyme of the pathway with different synthases to generate the biofuel precursors pinene and bisabolene (Fig. 5A). Pinene is a useful precursor molecule for various perfumes and bisabolene can be chemically hydrogenated to bisabolane which has nearly identical properties to D2 diesel fuel (Peralta-Yahya et al., 2011). We compared two pinene synthase homologs which produce similar levels of pinene while increased ratios of  $\beta$ -pinene compared to previous *in vitro* and *in vivo* studies (Fig. S16). When using 3.8  $\mu$ M of CFPS-derived monoterpene synthase, the limonene synthase produces higher amounts of product compared to the pinene synthases (Fig. 5B). A cell-free system composed of two pre-enriched lysates and seven CFPS-enriched reactions (including 1.0  $\mu$ M EcGPPS/FPPS (ispA) and 1.6  $\mu$ M AgBS) produces  $4.94 \pm 0.73$  mM (1010 mg/L) bisabolene after 72 h (Fig. 5C, Fig. S16). This is similar to the best bisabolene titer achieved in cells (912 mg/L) (Peralta-Yahya et al., 2011).

## Discussion

In this work, we demonstrated the potential of iPROBE to accelerate Design-Build-Test cycles for metabolic engineering. We applied iPROBE to the limonene biosynthesis pathway, representing the longest heterologous pathway utilized by iPROBE (nine steps) to date. We tested over 580 conditions of different enzyme homologs, enzyme concentrations, and cofactor conditions; this dataset is available in Supplementary Data File 1. The best performing reaction (using enzyme set 9.0) improved production of limonene by 25-fold from our initial conditions (enzyme set 1.0), producing  $4.49 \pm 0.14$  mM (610 mg/L) limonene in 24 h (Fig. S16). These rates and titers are similar to recent *in vivo* efforts (Table S4), though lower than a cell-free system utilizing purified enzymes that lacks competing side reactions (Korman et al., 2017).

Our results have several key features. First, our rapid, cell-free framework facilitates the study of a large number of pathway combinations. Already, cell-free prototyping has proved useful for optimizing several enzymatic pathways including isoprenoids (Dudley et al., 2016), fatty acids (Liu et al., 2010), farnesene (Zhu et al., 2014), phenylalanine (Ding et al., 2016), non-oxidative glycolysis (Bogorad et al., 2013), polyhydroxyalkanoates (Kelwick et al., 2018), 1,4-butanediol (Wu et al., 2015, 2017), styrene (Grubbe et al., 2020), and 3-hydroxybutyrate/n-butanol (Karim et al., 2019). Here, we used CFPS to express and study numerous enzyme homologs. The CFPS approach permitted production of active enzyme in hours without requiring protein purification or extensive expression optimization. This enabled the creation of multiple cell-free biosynthesis “units” that could be assembled modularly, in a mix-and-match fashion, to explore hundreds of distinct biosynthetic pathways. As a result, we found several enzyme steps including GPPS, IDI, and MK that showed strong differences between homologs. Specifically, we identified PgGPPS, SIIDI, and MmMK (Fig. S13) as promising candidates for further efforts to improve *in vivo* isoprenoid titers. Supporting our discoveries, two recent efforts utilized MmMK in place of ScMK to produce 1.29 g/L limonene (Wu et al., 2019) and to improve isoprene titers 1.4-fold (Li et al., 2019).

Another important feature of our work is that we identified enzyme sets with high activity across a range of cofactor concentrations. A key advantage of cell-free systems is that they enable the experimenter to directly manipulate the system, bypassing limitations on molecular transport across the cell wall. We used this feature to perform pathway optimizations under different cofactor concentrations to select enzymes that were robust and active under multiple conditions. To our knowledge, this kind of iterative, combinatorial strategy has yet to be pursued. While trends of relative homolog activity are similar across



**Fig. 4.** Iterative testing of enzyme sets at four different cofactor conditions identifies homologs with robust activity. (A) Conceptual approach: Starting with enzyme set 2.2, active homologs of GPPS were substituted for the default GPPS (*Pa*GPPS). Each GPPS homolog (orange) was tested under four different cofactor conditions and the resulting TREE scores averaged to rank each enzyme set. The top two sets were carried forward into the next iterative experiment in which all active homologs of IDI (yellow) were tested. The top two sets plus the best performing *St*GPPS sets were again carried forward and all active PMD homologs (green) were tested. Each subsequent iterative experiment used the top five conditions from the previous iteration to test active PMK (blue), PMD (purple), and HMGR (magenta) enzymes in sequence. (B) TREE scores of 408 reactions where each bar is a unique cofactor/enzyme set. Error bars represent propagated error (see Appendix S2). (C) The TREE score of each enzyme set was averaged across all four cofactor conditions and the highest score plotted to compare each homolog as a single value. The black bar represents the starting enzyme set 2.1. (D) Production of limonene (mM) and other metabolites over the course of the reaction using enzyme set 9.0. The concentration of each enzyme is 0.2  $\mu$ M *Bp*HMGR, 0.1  $\mu$ M *Mm*MMK, 0.2  $\mu$ M *Pz*PMK, 0.2  $\mu$ M *Sc*PMD, 0.2  $\mu$ M *SI*DI, and 1.0  $\mu$ M *Pg*GPPS plus pre-enriched lysates for *Ec*ACAT, *Sc*HMGS, and *Ms*LS; see Table S3 for more detailed description of the reaction components. Values represent averages ( $n = 3$ ) and error bars represent 1 standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)


different cofactor conditions, there are exceptions such as *Pz*PMK, *Sa*MMK, *Sa*HMGR, and *St*GPPS (Fig. S13; Fig. S15). Coordinately tuning enzyme homologs, enzyme concentrations, and cofactor concentrations together using data-driven design could facilitate improved pathway performance in metabolic engineering campaigns (Karim et al., 2019). Additional studies in multiple, distinct pathways, guided by machine learning, could elucidate new approaches toward efficient engineering efforts.

Future developments will seek to build upon and improve our efforts to design and optimize biosynthetic pathways using iPROBE. For example, correlations between cell-free optimized pathways and cellular designs could be established. In addition, enhancements to the TREE score, which consolidates three performance parameters (final titer, initial rate, and enzyme solubility) into a single metric, are warranted. While the TREE score provides an easy-to-use strategy for pathway ranking, it is sensitive to small changes in initial rate and the effect of enzyme solubility is relatively small. Thus, refining the TREE

score (e.g., by weighting each factor) to better correlate *in vitro* and *in vivo* data will help identify the minimal amount of cell-free data needed to inform pathway design. Finally, our isoprenoid prototyping platform could be adapted for alternate pathway routes that utilize neryl pyrophosphate as a substrate for monoterpene syntheses rather than GPP (Cheng et al., 2019; Ignea et al., 2019; Wu et al., 2019) or produce IPP and DMAPP using prenol or isoprenol as an intermediate (Chatzivasilieiou et al., 2019; Clomburg et al., 2019; Lund et al., 2019; Ward et al., 2019).

Looking forward, we anticipate that cell-free prototyping will facilitate rapid design-build-test cycles for identifying the best sets of enzymes to carry out a defined molecular transformation. In addition, the iPROBE framework could be adapted to other pathways for screening enzyme activity, testing for interacting effects between component parts, and analysis of byproduct pathways. iPROBE is particularly well suited for this endeavor because it can assess large numbers (500+) of enzyme combinations and cofactor conditions





**Fig. 5. Synthesis of additional terpenes including biofuel precursors pinene and bisabolene.** (A) Various terpene synthases can produce different products from the common GPP precursor. (B) Comparison of limonene and pinene production from glucose using CFPS-derived terpene synthases. Pinene synthases (PS) were encoded by sequences from *Abies grandis* (Grand fir) and *Picea abies* (Norway spruce). (C) Production of bisabolene from glucose by CFPS-enriched reactions containing farnesyl diphosphate synthase (EcFPPS encoded by *ispA*) from *E. coli* and bisabolene synthase (BS) from *Abies grandis*. Limonene, pinene, and bisabolene synthesis reactions use enzyme set 10.0 (see Table S3) and are supplemented with 5 mM NAD<sup>+</sup>, 1 mM CoA, and 1 mM ATP. Values represent averages (n = 3) and error bars represent 1 standard deviation. Fig. S16 depicts the accumulation of terpenoids over time.

without requiring large-scale DNA assembly or metabolic engineering of living cells. It is also able to identify potential synergies between enzymatic steps that can only come from studying sets of enzymes in the context of the full biosynthetic pathway. These abilities will be synergistically enhanced as new methods are developed for measuring target metabolites at high throughput (O’Kane et al., 2019). The approach reported here will thus advance efforts to design, build, and test any metabolic pathway of choice.

#### CRedit authorship contribution statement

**Quentin M. Dudley:** Conceptualization, Investigation, Formal analysis, Writing - original draft. **Ashty S. Karim:** Conceptualization, Formal analysis, Writing - review & editing. **Connor J. Nash:** Investigation. **Michael C. Jewett:** Conceptualization, Supervision, Writing - review & editing.

#### Declaration of competing interest

A.S.K., Q.M.D. and M.C.J. are co-inventors on U.S. provisional patent application that incorporates discoveries described in this manuscript. All other authors declare no conflicts.

#### Acknowledgements

We gratefully acknowledge the Department of Energy (BER grant: DE-SC0018249), the Joint Genome Institute Community Science Program (Project 503280), the David and Lucile Packard Foundation (2011–37152), and the Dreyfus Teacher-Scholar Program for funding and support. The work conducted by the U.S. Department of Energy Joint Genome Institute, a DOE Office of Science User Facility, is supported by the Office of Science of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. QMD is funded, in part, by the Northwestern Molecular Biophysics Training Program supported by NIH via NIGMS (5T32 GM008382). We also thank Will Bothfeld for helpful discussions and Do Soon Kim for advice on developing supplemental figures.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ymben.2020.05.006>.

#### References

- Alonso-Gutierrez, J., Kim, E.-M., Batth, T.S., Cho, N., Hu, Q., Chan, L.J.G., Petzold, C.J., Hillson, N.J., Adams, P.D., Keasling, J.D., 2015. Principal component analysis of proteomics (PCAP) as a tool to direct metabolic engineering. *Metab. Eng.* 28, 123–133.
- Benjamin, K.R., Silva, I.R., Cherubim, J.P., McPhee, D., Paddon, C.J., 2016. Developing commercial production of semi-synthetic artemisinin, and of β-farnesene, an isoprenoid produced by fermentation of Brazilian sugar. *J. Braz. Chem. Soc.* 27, 1339–1345.
- Berry, A., Huembelin, M., Lopez-Ulibarri, R., 2009. Production of coenzyme Q-10. US20090226986 A1.
- Berry, A., Janssens, D., Huembelin, M., Jore, J.P., Hoste, B., Cleenwerck, I., Vancanneyt, M., Bretzel, W., Mayer, A.F., Lopez-Ulibarri, R., 2003. *Paracoccus zeaxanthinifaciens* sp. nov., a zeaxanthin-producing bacterium. *Int. J. Syst. Evol. Microbiol.* 53, 231–238.
- Bogorad, I.W., Lin, T.-S., Liao, J.C., 2013. Synthetic non-oxidative glycolysis enables complete carbon conservation. *Nature* 502, 693–697.
- Bohlmann, J., Keeling, C.I., 2008. Terpenoid biomaterials. *Plant J.* 54, 656–669.
- Carlson, E.D., Gan, R., Hodgman, C.E., Jewett, M.C., 2012. Cell-free protein synthesis: applications come of age. *Biotechnol. Adv.* 30, 1185–1194.
- Casini, A., Chang, F.-Y., Eluere, R., King, A.M., Young, E.M., Dudley, Q.M., Karim, A., Pratt, K., Bristol, C., Forget, A., Ghodasara, A., Warden-Rothman, R., Gan, R., Cristofaro, A., Borujeni, A.E., Ryu, M.-H., Li, J., Kwon, Y.-C., Wang, H., Tatsis, E., Rodriguez-Lopez, C., O’Connor, S.E., Medema, M.H., Fischbach, M.A., Jewett, M.C., Voigt, C.A., Gordon, D.B., 2018. A pressure test to make 10 molecules in 90 days: external evaluation of methods to engineer biology. *J. Am. Chem. Soc.* 140, 4302–4316.
- Chatzivasilieiou, A.O., Ward, V., Edgar, S.M., Stephanopoulos, G., 2019. Two-step pathway for isoprenoid synthesis. *Proc. Natl. Acad. Sci. U.S.A.* 116, 506–511.
- Chen, X., Zhang, C., Zou, R., Zhou, K., Stephanopoulos, G., Too, H.P., 2013. Statistical experimental design guided optimization of a one-pot biphasic multienzyme total synthesis of amorph-4, 11-diene. *PLoS One* 8, e79650.
- Chen, Z., Kibler, R.D., Hunt, A., Busch, F., Pearl, J., Jia, M., VanAernum, Z.L., Wicky, B.I., Dods, G., Liao, H., Wilken, M.S., Ciarlo, C., Green, S., El-Samad, H., Stamatoyannopoulos, J., Wysocki, V.H., Jewett, M.C., Boyken, S.E., Baker, D., 2020. De novo design of protein logic gates. *Science* 368, 78–84.
- Cheng, S., Liu, X., Jiang, G., Wu, J., Zhang, J.-L., Lei, D., Yuan, Y.-J., Qiao, J., Zhao, G.-R., 2019. Orthogonal engineering of biosynthetic pathway for efficient production of limonene in *Saccharomyces cerevisiae*. *ACS Synth. Biol.* 8, 968–975.
- Clomburg, J.M., Qian, S., Tan, Z., Cheong, S., Gonzalez, R., 2019. The isoprenoid alcohol pathway, a synthetic route for isoprenoid biosynthesis. *Proc. Natl. Acad. Sci. U.S.A.* 116, 12810–12815.
- Des Soye, B.J., Gerbasi, V.R., Thomas, P.M., Kelleher, N.L., Jewett, M.C., 2019. A highly productive, one-pot cell-free protein synthesis platform based on genomically re-coded *Escherichia coli*. *Cell Chem. Biol.* 26, 1743–1754.
- Ding, D., Liu, Y., Xu, Y., Zheng, P., Li, H., Zhang, D., Sun, J., 2016. Improving the production of L-phenylalanine by identifying key enzymes through multi-enzyme reaction system *in vitro*. *Sci. Rep.* 6.
- Dirkmann, M., Nowack, J., Schulz, F., 2018. An *in vitro* biosynthesis of sesquiterpenes starting from acetic acid. *Chembiochem* 19, 2146–2151.
- Dudley, Q.M., Anderson, K.C., Jewett, M.C., 2016. Cell-free mixing of *Escherichia coli* crude extracts to prototype and rationally engineer high-titer mevalonate synthesis. *ACS Synth. Biol.* 5, 1578–1588.
- Dudley, Q.M., Karim, A.S., Jewett, M.C., 2015. Cell-free metabolic engineering: biomaterial manufacturing beyond the cell. *Biotechnol. J.* 10, 69–82.
- Dudley, Q.M., Nash, C.J., Jewett, M.C., 2019. Cell-free biosynthesis of limonene using *Escherichia coli* crude extracts. *Synth. Biol.* 4, ysz003.
- Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and high

- throughput. *Nucleic Acids Res.* 32, 1792–1797.
- Farala, V., Akhtar, T.A., Nguyen, T.T., Spyropoulou, E.A., Bleeker, P.M., Schuvinhold, I., Matsuba, Y., Bonini, M.E., Schillmiller, A.L., Last, R.L., Schuurink, R.C., Pichersky, E., 2011. The tomato terpene synthase gene family. *Plant Physiol.* 157, 770–789.
- Francis, D.M., Page, R., 2010. Strategies to optimize protein expression in *E. coli*. *Curr. Protein Pept. Sci.* 61, 5–24 1-5.24. 29.
- Fujiwara, K., Katayama, T., Nomura, S.-i. M., 2013. Cooperative working of bacterial chromosome replication proteins generated by a reconstituted protein expression system. *Nucleic Acids Res.* 41, 7176–7183.
- George, K.W., Alonso-Gutierrez, J., Keasling, J.D., Lee, T.S., 2015. Isoprenoid drugs, biofuels, and chemicals—artemisinin, farnesene, and beyond. *Advances in biochemical engineering/biotechnology* 148, 355–389.
- Gibson, D.G., Young, L., Chuang, R.-Y., Venter, J.C., Hutchison, C.A., Smith, H.O., 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* 6, 343–345.
- Grubbe, W.S., Rasor, B.J., Kruger, A., Jewett, M.C., Karim, A.S., 2020. Cell-free Styrene Biosynthesis at High Titrers. *bioRxiv* 979302.
- Huang, A., Nguyen, P.Q., Stark, J.C., Takahashi, M.K., Donghia, N., Ferrante, T., Dy, A.J., Hsu, K.J., Dubner, R.S., Pardee, K., Jewett, M.C., Collins, J.J., 2018. BioBits™ Explorer: a modular synthetic biology education kit. *Sci. Adv.* 4 eaat5105.
- Ignea, C., Raadam, M.H., Motawia, M.S., Makris, A.M., Vickers, C.E., Kampranis, S.C., 2019. Orthogonal monoterpenoid biosynthesis in yeast constructed on an isomeric substrate. *Nat. Commun.* 10, 1–15.
- Jaroentomechai, T., Stark, J.C., Natarajan, A., Glasscock, C.J., Yates, L.E., Hsu, K.J., Mrksich, M., Jewett, M.C., DeLisa, M.P., 2018. Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery. *Nat. Commun.* 9, 1–11.
- Jervis, A.J., Carbonell, P., Vinaixa, M., Dunstan, M.S., Hollywood, K.A., Robinson, C.J., Rattray, N.J., Yan, C., Swainston, N., Currin, A., Sung, R., Toogood, H., Taylor, S., Faulon, J.-L., Breitling, R., Takano, E., Scrutton, N.S., 2019. Machine learning of designed translational control allows predictive pathway optimization in *Escherichia coli*. *ACS Synth. Biol.* 8, 127–136.
- Jewett, M.C., Calhoun, K.A., Voloshin, A., Wu, J.J., Swartz, J.R., 2008. An integrated cell-free metabolic platform for protein production and synthetic biology. *Mol. Syst. Biol.* 4, 220.
- Jewett, M.C., Swartz, J.R., 2004. Mimicking the *Escherichia coli* cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. *Biotechnol. Bioeng.* 86, 19–26.
- Jongedijk, E., Cankar, K., Buchhaupt, M., Schrader, J., Bouwmeester, H., Beekwilder, J., 2016. Biotechnological production of limonene in microorganisms. *Appl. Microbiol. Biotechnol.* 100, 2927–2938.
- Karim, A.S., Dudley, Q.M., Juminaga, A., Yuan, Y., Crowe, S.A., Heggstad, J.T., Abdalla, T., Grubbe, W., Rasor, B., Coar, D., Torculas, M., Krein, M., Liew, F., Quattlebaum, A., Jensen, R.O., Stuart, J., Simpson, S.D., Köpke, M., Jewett, M.C., 2019. In vitro prototyping and rapid optimization of biosynthetic enzymes for cellular design. *bioRxiv* 685768.
- Karim, A.S., Heggstad, J.T., Crowe, S.A., Jewett, M.C., 2018. Controlling cell-free metabolism through physicochemical perturbations. *Metab. Eng.* 45, 86–94.
- Karim, A.S., Jewett, M.C., 2016. A cell-free framework for rapid biosynthetic pathway prototyping and enzyme discovery. *Metab. Eng.* 36, 116–126.
- Kataeva, I., Chang, J., Xu, H., Luan, C.-H., Zhou, J., Uversky, V.N., Lin, D., Horanyi, P., Liu, Z., Ljungdahl, L.G., 2005. Improving solubility of *Shewanella oneidensis* MR-1 and *Clostridium thermocellum* JW-20 proteins expressed into *Escherichia coli*. *J. Proteome Res.* 4, 1942–1951.
- Kelwick, R., Ricci, L., Chee, S.M., Bell, D., Webb, A.J., Freemont, P.S., 2018. Cell-free prototyping strategies for enhancing the sustainable production of polyhydroxyalkanoates bioplastics. *Synth. Biol.* 3, ysy016.
- Kightlinger, W., Duncker, K.E., Ramesh, A., Thames, A.H., Natarajan, A., Stark, J.C., Yang, A., Lin, L., Mrksich, M., DeLisa, M.P., 2019. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways. *Nat. Commun.* 10, 1–13.
- Korman, T.P., Opgenorth, P.H., Bowie, J.U., 2017. A synthetic biochemistry platform for cell free production of monoterpenes from glucose. *Nat. Commun.* 8, 15526.
- Korman, T.P., Sahachartsiri, B., Li, D., Vinokur, J.M., Eisenberg, D., Bowie, J.U., 2014. A synthetic biochemistry system for the *in vitro* production of isoprene from glycolysis intermediates. *Protein Sci.* 23, 576–585.
- Kwon, Y.-C., Jewett, M.C., 2015. High-throughput preparation methods of crude extract for robust cell-free protein synthesis. *Sci. Rep.* 5, 8663.
- Leferink, N.G., Jervis, A.J., Zebec, Z., Toogood, H.S., Hay, S., Takano, E., Scrutton, N.S., 2016. A 'plug and Play'Platform for the production of diverse monoterpene hydrocarbon scaffolds in *Escherichia coli*. *Chemistry* 1, 1893–1896.
- Li, J., Wang, H., Kwon, Y.C., Jewett, M.C., 2017. Establishing a high yielding streptomycin-based cell-free protein synthesis system. *Biotechnol. Bioeng.* 114, 1343–1353.
- Li, M., Chen, H., Liu, C., Guo, J., Xu, X., Zhang, H., Nian, R., Xian, M., 2019. Improvement of isoprene production in *Escherichia coli* by rational optimization of RBSs and key enzymes screening. *Microb. Cell Factories* 18, 4.
- Lin, L., Kightlinger, W., Prabhu, S.K., Hockenberry, A.J., Li, C., Wang, L.-X., Jewett, M.C., Mrksich, M., 2020. Sequential glycosylation of proteins with substrate-specific N-glycosyltransferases. *ACS Cent. Sci.* 6, 144–154.
- Liu, T., Vora, H., Khosla, C., 2010. Quantitative analysis and engineering of fatty acid biosynthesis in *E. coli*. *Metab. Eng.* 12, 378–386.
- Lund, S., Hall, R., Williams, G.J., 2019. An artificial pathway for isoprenoid biosynthesis decoupled from native hemiterpene metabolism. *ACS Synth. Biol.* 8, 232–238.
- Ma, S.M., Garcia, D.E., Redding-Johanson, A.M., Friedland, G.D., Chan, R., Batth, T.S., Haliburton, J.R., Chivian, D., Keasling, J.D., Petzold, C.J., Lee, T.S., Chhabra, S.R., 2011. Optimization of a heterologous mevalonate pathway through the use of variant HMG-CoA reductases. *Metab. Eng.* 13, 588–597.
- Maeda, H.A., 2019. Harnessing evolutionary diversification of primary metabolism for plant synthetic biology. *J. Biol. Chem.* 294, 16549–16566.
- Meyer, A.J., Segall-Shapiro, T.H., Glassey, E., Zhang, J., Voigt, C.A., 2019. *Escherichia coli* "Marionette" strains with 12 highly optimized small-molecule sensors. *Nat. Chem. Biol.* 15, 196.
- Miguez, A.M., McNERney, M.P., Styczynski, M.P., 2019. Metabolic profiling of *Escherichia coli*-based cell-free expression systems for process optimization. *Ind. Eng. Chem. Res.* 58, 2242–22482.
- Nowroozi, F.F., Baidoo, E.E., Ermakov, S., Redding-Johanson, A.M., Batth, T.S., Petzold, C.J., Keasling, J.D., 2014. Metabolic pathway optimization using ribosome binding site variants and combinatorial gene assembly. *Appl. Microbiol. Biotechnol.* 98, 1567–1581.
- O'Kane, P.T., Dudley, Q.M., McMillan, A.K., Jewett, M.C., Mrksich, M., 2019. High-throughput mapping of CoA metabolites by SAMDI-MS to optimize the cell-free biosynthesis of HMG-CoA. *Sci. Adv.* 5 eaaw9180.
- Paddon, C., Westfall, P., Pitera, D., Benjamin, K., Fisher, K., McPhee, D., Leavell, M., Tai, A., Main, A., Eng, D., Polichuk, D.R., Teoh, K.H., Reed, D.W., Treynor, T., Lenihan, J., Jiang, H., Fleck, M., Bajad, S., Dang, G., Dengrove, D., Diola, D., Dorin, G., Ellens, K.W., Fickes, S., Galazzo, J., Gaucher, S.P., Geistlinger, T., Henry, R., Hepp, M., Horning, T., Iqbal, T., Kizer, L., Lieu, B., Melis, D., Moss, N., Regentin, R., Secrest, S., Tsuruta, H., Vazquez, R., Westblade, L.F., Xu, L., Yu, M., Zhang, Y., Zhao, L., Lievense, J., Covello, P.S., Keasling, J.D., Reiling, K.K., Renninger, N.S., Newman, J.D., 2013. High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature* 496, 528–532.
- Peralta-Yahya, P.P., Ouellet, M., Chan, R., Mukhopadhyay, A., Keasling, J.D., Lee, T.S., 2011. Identification and microbial production of a terpene-based advanced biofuel. *Nat. Commun.* 2, 483.
- Pisierchio, A., Ghose, R., Cowburn, D., 2009. Optimized bacterial expression and purification of the c-Src catalytic domain for solution NMR studies. *J. Biomol. NMR* 44, 87–93.
- Primak, Y.A., Du, M., Miller, M.C., Wells, D.H., Nielsen, A.T., Weyler, W., Beck, Z.Q., 2011. Characterization of a feedback-resistant mevalonate kinase from the archaeon *Methanosarcina mazei*. *Appl. Environ. Microbiol.* 77, 7772–7778.
- Rodriguez, S.B., Leyh, T.S., 2014. An enzymatic platform for the synthesis of isoprenoid precursors. *PLoS One* 9, e105594.
- Scheer, M., Grote, A., Chang, A., Schomburg, I., Munaretto, C., Rother, M., Söhngen, C., Stelzer, M., Thiele, J., Schomburg, D., 2010. BRENDA, the enzyme information system in 2011. *Nucleic Acids Res.* 39, D670–D676.
- Schmidt, K., Petersen, J., Munkert, J., Egerer-Sieber, C., Hornig, M., Müller, Y.A., Kreis, W., 2018. PRISES (progesterone 5β-reductase and/or iridoid synthase-like 1, 4-enone reductases): catalytic and substrate promiscuity allows for realization of multiple pathways in plant metabolism. *Phytochemistry* 156, 9–19.
- Schuh, L.K., Weyler, C., Heinze, E., 2020. In-depth characterization of genome-scale network reconstructions for the *in vitro* synthesis in cell-free systems. *Biotechnol. Bioeng.* 117, 1137–1147.
- Silverman, A.D., Karim, A.S., Jewett, M.C., 2019. Cell-free gene expression: an expanded repertoire of applications. *Nat. Rev. Genet.* 21, 151–170.
- Smanski, M.J., Bhatia, S., Zhao, D., Park, Y., Woodruff, L.B., Giannoukos, G., Ciulla, D., Busby, M., Gordon, D.B., Densmore, D., Voigt, C.A., 2014. Functional optimization of gene clusters by combinatorial design and assembly. *Nat. Biotechnol.* 32, 1241–1249.
- Stark, J.C., Huang, A., Hsu, K.J., Dubner, R.S., Forbrook, J., Marshall, S., Rodriguez, F., Washington, M., Rybnicky, G.A., Nguyen, B., Ottman, S., Palffy, C., Patel, A., Skweres, R., Koralewski, V., Wightkin, W., Martinez, T., Jewett, M.C., 2019. BioBits health: classroom Activities exploring engineering, biology, and human health with fluorescent readouts. *ACS Synth. Biol.* 8, 1001–1009.
- Stark, J.C., Huang, A., Nguyen, P.Q., Dubner, R.S., Hsu, K.J., Ferrante, T.C., Anderson, M., Kanapkyte, A., Mucha, Q., Packett, J.S., Patel, P., Patel, R., Qaq, D., Zondor, T., Burke, J., Martinez, T., Miller-Berry, A., Puppala, A., Reichert, K., Schmid, M., Brand, L., Hill, L.R., Chellawamy, J.F., Faheem, N., Fetherling, S., Gong, E., Gonzales, E.M., Granito, T., Koritsaris, J., Nguyen, B., Ottman, S., Palffy, C., Patel, A., Skweres, S., Slaton, A., Woods, T., Donghia, N., Pardee, K., Collins, J.J., Jewett, M.C., 2018. BioBits™ Bright: a fluorescent synthetic biology education kit. *Sci. Adv.* 4, eaat5107.
- Swartz, J.R., Jewett, M.C., Woodrow, K.A., 2004. Cell-free protein synthesis with prokaryotic combined transcription-translation. In: Balbás, P., Lorence, A. (Eds.), *Recombinant Gene Expression: Reviews and Protocols*. Springer, pp. 169–182.
- Tsuruta, H., Paddon, C.J., Eng, D., Lenihan, J.R., Horning, T., Anthony, L.C., Regentin, R., Keasling, J.D., Renninger, N.S., Newman, J.D., 2009. High-level production of amorpha-4, 11-diene, a precursor of the antimalarial agent artemisinin, in *Escherichia coli*. *PLoS One* 4, e4489.
- Ward, V.C., Chatzivasileiou, A.O., Stephanopoulos, G., 2019. Cell free biosynthesis of isoprenoids from isopentenol. *Biotechnol. Bioeng.* 116, 3269–3281.
- Wu, J., Cheng, S., Cao, J., Qiao, J., Zhao, G.-R., 2019. Systematic optimization of limonene production in engineered *Escherichia coli*. *J. Agric. Food Chem.* 67, 7087–7097.
- Wu, Y.Y., Culler, S., Khandurina, J., Van Dien, S., Murray, R.M., 2015. Prototyping 1, 4-butanediol (BDO) biosynthesis pathway in a cell-free transcription-translation (TX-TL) system. *bioRxiv*, 017814.
- Wu, Y.Y., Sato, H., Huang, H., Culler, S.J., Khandurina, J., Nagarajan, H., Yang, T.H., Van Dien, S., Murray, R.M., 2017. System-level studies of a cell-free transcription-translation platform for metabolic engineering. *bioRxiv* 172007.
- Yang, L., Wang, C., Zhou, J., Kim, S.-W., 2016. Combinatorial engineering of hybrid mevalonate pathways in *Escherichia coli* for protoilludene production. *Microb. Cell Factories* 15, 14.
- Zhou, S., Lyu, Y., Li, H., Koffas, M.A., Zhou, J., 2019. Fine-tuning the (2S)-naringenin synthetic pathway using an iterative high-throughput balancing strategy. *Biotechnol. Bioeng.* 116, 1392–1404.
- Zhu, F., Zhong, X., Hu, M., Lu, L., Deng, Z., Liu, T., 2014. In vitro reconstitution of mevalonate pathway and targeted engineering of farnesene overproduction in *Escherichia coli*. *Biotechnol. Bioeng.* 111, 1396–1405.